Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Crystalline cellulose simple occlusive dressing
The First People's Hospital of Lianyungang
Split-thickness Skin Graft Donor Sites
1 trial -
Cyclophosphamide
Children's Hospital of Fudan University
Stage III Kidney Wilms Tumor
1 trial -
Cyclophosphamide Injection 500 mg., Vincristine Sulfate 1 mg/ml solution for injection, Cisplatin 1 mg/ml concentrate for solution for infusion, Temodal 100 mg hard capsules, Etoposide 20 mg/ml Concentrate for Solution for Infusion, Thiotepa 15 mg Powder for solution for injection , Qarziba 4.5 mg/mL concentrate for solution for infusion, Melphalan 50 mg concentrate and solvent for solution for injection/infusion, Busulfan 6 mg/ml concentrate for solution for infusion, CARBOPLATINE MEDAC 10 mg/mL, solution
The George Institute
Patients with High Risk Neuroblastoma
1 trial -
Cytarabine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
AML
3 trials -
Cytarabine
The First People's Hospital of Lianyungang
Leukemia
1 trial -
DAPAGLIFLOZIN, Placebo for dapagliflozin film-coated tablets 10 mg
Disc Medicine
Combined endpoint of all-cause mortality, kidney failure, and hospitalization for heart failure in the overall study population
1 trial -
DAUNORUBICIN HYDROCHLORIDE, FLUDARABINE, MYLOTARG 5 mg powder for concentrate for solution for infusion, CYCLOPHOSPHAMIDE, TREOSULFAN, CYTARABINE, BUSULFAN
Fondazione Telethon ETS
Favorable-intermediate-risk Acute Myeloid Leukemia
1 trial -
DEGARELIX, GOSERELIN, TRIPTORELIN, LEUPRORELIN ACETATE, DEGARELIX, DEGARELIX, TRIPTORELIN , DEGARELIX, LEUPRORELIN ACETATE, TRIPTORELIN
Ningbo Cancer Hospital
very high risk localized or locally advanced prostate cancer
1 trial -
DEXAMETHASONE , FLUDARABINE , CISPLATIN , OXALIPLATIN , CARBOPLATIN , LENALIDOMIDE , RITUXIMAB , TOCILIZUMAB , CYCLOPHOSPHAMIDE , BENDAMUSTINE , TISAGENLECLEUCEL, IFOSFAMIDE , MELPHALAN , CYTARABINE , CARMUSTINE , IBRUTINIB , ETOPOSIDE , GEMCITABINE
Novartis Pharmaceuticals
Adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
1 trial -
DEXAMETHASONE PHOSPHATE, Placebo of dexamethasone
Pari Pharma GmbH
respiratory distress due to upper airway obstruction in child
1 trial -
DEXAMETHASONE, RITUXIMAB, BLINATUMOMAB, MERCAPTOPURINE, RITUXIMAB, BLINATUMOMAB, CYCLOPHOSPHAMIDE, PREDNISONE, CYTARABINE, IDARUBICIN, PREDNISOLONE, METHOTREXATE SODIUM, DEXAMETHASONE, DEXAMETHASONE, CYCLOPHOSPHAMIDE, PEGASPARGASE, DOXORUBICIN, CYTARABINE, DEXAMETHASONE, MERCAPTOPURINE, VINCRISTINE SULFATE, METHOTREXATE SODIUM, METHOTREXATE SODIUM, VINCRISTINE SULFATE, ASPARAGINASE, CRISANTASPASE, METHOTREXATE SODIUM
Amgen
Newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia in older adults
1 trial -
DOTAREM 0,5 mmol/mL, solution injectable, GADOPICLENOL
Guerbet
Suspected Vascular Disease of supra-aortic (carotid/vertebrobasilar), peripheral or abdominal/renal arteries
1 trial -
DOXORUBICIN, EPIRUBICIN, CISPLATIN, OPDIVO 10 mg/mL concentrate for solution for infusion., MITOMYCIN, LIPIODOL ULTRA FLUIDE 480 mg/ml, solution injectable, IDARUBICIN
Ningbo Cancer Hospital
Intermediate stage Hepatocellular carcinoma
1 trial -
DOXORUBICIN, Pralatrexate, PREDNISONE, Belinostat, VINCRISTINE SULFATE, CYCLOPHOSPHAMIDE
Lacuna Pharma Pty Ltd
Peripheral T-Cell Lymphoma
1 trial -
DOXYCYCLINE SANDOZ 100 mg, comprimΓ© sΓ©cable, EXTENCILLINE 2,4 MUI, poudre et solvant pour suspension injectable IM
Pari Pharma GmbH
early syphilis
1 trial -
DR-5001
Teva Pharma GmbH
Respiratory Tract Diseases
1 trial -
DURVALUMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., CISPLATIN, ETOPOSIDE, Olaparib, CARBOPLATIN, MK-7339, Olaparib Placebo, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, PEMETREXED, PACLITAXEL
Merck Sharp and Dohme
Non-small cell lung cancer
1 trial -
Dactinomycin
Children's Hospital of Fudan University
Adult Kidney Wilms Tumor
1 trial -
Dapagliflozin+Standard Treatment for 12 weeks,washout period for 4 weeksοΌthen Standard Treatment alone for12 weeks
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Pediatric Hereditary Kidney Diseases
1 trial -
Daratumumab, DARATUMUMAB, LENALIDOMIDE, DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE
Celltrion Healthcare Australia Pty Ltd
Refractory or Relapsed Multiple Myeloma
1 trial -
Daunorubicin/Idarubicin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
AML, Adult
1 trial -
Decitabine
The First People's Hospital of Lianyungang
Thrombocytopenia
1 trial -
Decitabine
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
Decitabine
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia, Adult
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources